1
|
Verzele D, Ruiz García Y, Madder A. Untapped Opportunities of Resin-to-Resin Transfer Reactions (RRTR) for the Convergent Assembly of Multivalent Peptide Conjugates. Chemistry 2020; 26:4701-4705. [PMID: 31997431 DOI: 10.1002/chem.202000434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Indexed: 11/07/2022]
Abstract
Handling of the individual fragments remains a bottleneck in the convergent assembly of peptides. Overlooked since the emergence of ligation chemistries during the past two decades, so-called resin-to-resin transfer reactions (RRTR) are here described as a strategic shortcut in this context. Condensation of the involved moieties at an acceptor resin is facilitated by shuttling peptide segments directly from a donor resin in a one-pot fashion. The straightforward synthesis of a sterically constrained 13-mer peptidosteroid model illustrates the utility of this approach, presenting the first successful application of the RRTR methodology in the field of multivalent design and bioconjugation. Relying on established procedures to generate, monitor and isolate intermediates and products, the solid-phase nature of the entire strategy allows for the fast construction of polypeptide adducts and libraries thereof. As such, a rejuvenated use and new opportunities for RRTR are reported.
Collapse
Affiliation(s)
- Dieter Verzele
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 (S4), 9000, Ghent, Belgium
| | - Yara Ruiz García
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 (S4), 9000, Ghent, Belgium
| | - Annemieke Madder
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 (S4), 9000, Ghent, Belgium
| |
Collapse
|
2
|
Dirksen A, Davis KA, Collins JT, Bhattacharya K, Finneman JI, Pepin EL, Ryczek JS, Brown PW, Wellborn WB, Mangalathillam R, Evans BP, Pozzo MJ, Finn RF. Process development of a FGF21 protein-antibody conjugate. Biopolymers 2017; 110. [PMID: 28948603 DOI: 10.1002/bip.23042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 07/27/2017] [Accepted: 08/01/2017] [Indexed: 11/09/2022]
Abstract
A scalable, viable process was developed for the Fibroblast Growth Factor 21 (FGF21) protein-antibody conjugate, CVX-343, an extended half-life therapeutic for the treatment of metabolic disease. CVX-343 utilizes the CovX antibody scaffold technology platform that was specifically developed for peptide and protein half-life extension. CVX-343 is representative of a growing number of complex novel peptide- and protein-based bioconjugate molecules currently being explored as therapeutic candidates. The complexity of these bioconjugates, assembled using well-established chemistries, can lead to very difficult production schemes requiring multiple starting materials and a combination of diverse technologies. Key improvements had to be made to the original CVX-343 Phase 1 manufacturing process in preparation for Phase 3 and commercial manufacturing. A strategy of minimizing FGF21A129C dimerization and stabilizing the FGF21A129C Drug Substance Intermediate (DSI), linker, and activated FGF21 intermediate was pursued. The use of tris(2-carboxyethyl)phosphine (TCEP) to prevent FGF21A129C dimerization through disulfide formation was eliminated. FGF21A129C dimerization and linker hydrolysis were minimized by formulating and activating FGF21A129C at acidic instead of neutral pH. An activation use test was utilized to guide FGF21A129C pooling in order to minimize misfolds, dimers, and misfolded dimers in the FGF21A129C DSI. After final optimization of reaction conditions, a process was established that reduced the consumption of FGF21A129C by 36% (from 4.7 to 3.0 equivalents) and the consumption of linker by 55% (from 1.4 to 0.95 equivalents for a smaller required amount of FGF21A129C ). The overall process time was reduced from ∼5 to ∼3 days. The product distribution improved from containing ∼60% to ∼75% desired bifunctionalized (+2 FGF21) FGF21-antibody conjugate in the crude conjugation mixture and from ∼80% to ∼85% in the final CVX-343 Drug Substance (DS), while maintaining the same overall process yield based on antibody scaffold input.
Collapse
Affiliation(s)
- Anouk Dirksen
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Keith A Davis
- Pfizer Inc. -BioTherapeutics Pharmaceutical Sciences: Analytical R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Joe T Collins
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Keshab Bhattacharya
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Jari I Finneman
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Erin L Pepin
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Jeffrey S Ryczek
- Pfizer Inc. -BioTherapeutics Pharmaceutical Sciences: Analytical R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Paul W Brown
- Pfizer Inc. -BioTherapeutics Pharmaceutical Sciences: Analytical R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - William B Wellborn
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Ratish Mangalathillam
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Brad P Evans
- Pfizer Inc. -BioTherapeutics Pharmaceutical Sciences: Statistics, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Mark J Pozzo
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| | - Rory F Finn
- Pfizer Inc.-BioTherapeutics Pharmaceutical Sciences: Bioprocess R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017
| |
Collapse
|
3
|
Gubeli RJ, Sonzini S, Podmore A, Ravn P, Scherman OA, van der Walle CF. Selective, non-covalent conjugation of synthetic peptides with recombinant proteins mediated by host-guest chemistry. Chem Commun (Camb) 2016; 52:4235-8. [PMID: 26911663 DOI: 10.1039/c6cc00405a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The combination of potent chemical moieties with biologically active proteins is key to some of today's most innovative therapeutic drugs. In order to obviate any chemical modification of the proteins, we present a novel and powerful strategy for the selective conjugation of recombinant protein domains with synthetically derived peptides via a cucurbit[8]uril host-guest chemistry approach.
Collapse
Affiliation(s)
- R J Gubeli
- Formulation Sciences, MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK.
| | - S Sonzini
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
| | - A Podmore
- Formulation Sciences, MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK.
| | - P Ravn
- Department of Antibody Discovery and Protein Engineering, MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK
| | - O A Scherman
- Melville Laboratory for Polymer Synthesis, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
| | - C F van der Walle
- Formulation Sciences, MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK.
| |
Collapse
|
4
|
Van Deventer JA, Le DN, Zhao J, Kehoe HP, Kelly RL. A platform for constructing, evaluating, and screening bioconjugates on the yeast surface. Protein Eng Des Sel 2016; 29:485-494. [PMID: 27515702 DOI: 10.1093/protein/gzw029] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 06/15/2016] [Accepted: 06/18/2016] [Indexed: 12/31/2022] Open
Abstract
The combination of protein display technologies and noncanonical amino acids (ncAAs) offers unprecedented opportunities for the high throughput discovery and characterization of molecules suitable for addressing fundamental and applied problems in biological systems. Here we demonstrate that ncAA-compatible yeast display facilitates evaluations of conjugation chemistry and stability that would be challenging or impossible to perform with existing mRNA, phage, or E. coli platforms. Our approach enables site-specific introduction of ncAAs into displayed proteins, robust modification at azide-containing residues, and quantitative evaluation of conjugates directly on the yeast surface. Moreover, screening allows for the selective enrichment of chemically modified constructs while maintaining a genotype-phenotype linkage with encoded azide functionalities. Thus, this platform is suitable for the high throughput characterization and screening of libraries of chemically modified polypeptides for therapeutic lead discovery and other biological applications.
Collapse
Affiliation(s)
- James A Van Deventer
- Chemical and Biological Engineering Department, Tufts University, 4 Colby Street Room 148, Medford, MA 02155, United States of America.,Koch Institute for Integrative Cancer Research.,Department of Chemical Engineering
| | - Doris N Le
- Koch Institute for Integrative Cancer Research.,Department of Chemical Engineering
| | - Jessie Zhao
- Koch Institute for Integrative Cancer Research.,Department of Chemical Engineering
| | - Haixing P Kehoe
- Chemical and Biological Engineering Department, Tufts University, 4 Colby Street Room 148, Medford, MA 02155, United States of America
| | - Ryan L Kelly
- Koch Institute for Integrative Cancer Research.,Department of Biological Engineering, Massachusetts Institute of Technology, 500 Main Street, Building 76 Room 289, Cambridge, MA 02139, United States of America
| |
Collapse
|
5
|
Yao H, Jiang F, Lu A, Zhang G. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs). Int J Mol Sci 2016; 17:E194. [PMID: 26848651 PMCID: PMC4783928 DOI: 10.3390/ijms17020194] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 01/28/2016] [Accepted: 01/28/2016] [Indexed: 11/16/2022] Open
Abstract
Antibody-drug conjugates (ADCs) have become a promising targeted therapy strategy that combines the specificity, favorable pharmacokinetics and biodistributions of antibodies with the destructive potential of highly potent drugs. One of the biggest challenges in the development of ADCs is the application of suitable linkers for conjugating drugs to antibodies. Recently, the design and synthesis of linkers are making great progress. In this review, we present the methods that are currently used to synthesize antibody-drug conjugates by using thiols, amines, alcohols, aldehydes and azides.
Collapse
Affiliation(s)
- Houzong Yao
- Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
| | - Feng Jiang
- Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
- Faculty of Materials Science and Chemical Engineering, the State Key Laboratory Base of Novel Functional Materials and Preparation Science, Ningbo University, Ningbo 315211, Zhejiang, China.
| | - Aiping Lu
- Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
| | - Ge Zhang
- Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
| |
Collapse
|
6
|
Catcott KC, McShea MA, Bialucha CU, Miller KL, Hicks SW, Saxena P, Gesner TG, Woldegiorgis M, Lewis ME, Bai C, Fleming MS, Ettenberg SA, Erickson HK, Yoder NC. Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. MAbs 2016; 8:513-23. [PMID: 26752675 DOI: 10.1080/19420862.2015.1134408] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by purification and biochemical analysis techniques that necessitate burdensome quantities of antibody. Here we describe a method, developed for the maytansinoid class of ADCs, enabling parallel conjugation of antibodies in 96-well format. The method utilizes ∼ 100 µg of antibody per well and requires <5 µg of ADC for characterization. We demonstrate the capabilities of this system using model antibodies. We also provide multiple examples applying this method to early-stage screening of maytansinoid ADCs. The method can greatly increase the throughput with which candidate ADCs can be screened in cell-based assays, and may be more generally applicable to high-throughput preparation and screening of different types of protein conjugates.
Collapse
Affiliation(s)
| | | | | | - Kathy L Miller
- c Novartis Institutes for Biomedical Research , Emeryville , CA
| | | | - Parmita Saxena
- b Novartis Institutes for Biomedical Research , Cambridge , MA
| | - Thomas G Gesner
- b Novartis Institutes for Biomedical Research , Cambridge , MA
| | | | | | - Chen Bai
- a ImmunoGen, Inc. , Waltham , MA
| | | | | | | | | |
Collapse
|
7
|
Coffey SB, Aspnes G, Londregan AT. Expedient Synthesis of N1-Substituted Triazole Peptidomimetics. ACS COMBINATORIAL SCIENCE 2015; 17:706-9. [PMID: 26562078 DOI: 10.1021/acscombsci.5b00150] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
A general procedure for the rapid diversification of peptide scaffolds is described. A one-pot click reaction between a peptide-alkyne and a series of in situ generated aryl/alkyl azides affords novel N1-substituted triazole peptidomimetics. This transformation is of broad scope, operates under mild conditions, and is parallel chemical synthesis compatible.
Collapse
Affiliation(s)
- Steven B. Coffey
- Pfizer Worldwide Medicinal Chemistry, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gary Aspnes
- Pfizer Worldwide Medicinal Chemistry, Eastern Point Road, Groton, Connecticut 06340, United States
- Pfizer Worldwide Medicinal Chemistry, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Allyn T. Londregan
- Pfizer Worldwide Medicinal Chemistry, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
8
|
Cserép GB, Herner A, Kele P. Bioorthogonal fluorescent labels: a review on combined forces. Methods Appl Fluoresc 2015; 3:042001. [DOI: 10.1088/2050-6120/3/4/042001] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|